Skip to main content
Alison (Rager) Sehgal, MD, Oncology, Pittsburgh, PA

AlisonR(Rager)SehgalMD

Oncology Pittsburgh, PA

Physician

Dr. Sehgal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Sehgal's full profile

Already have an account?

  • Office

    5115 Centre Ave
    Upmc Cancer Pavillion. 5th Floor
    Pittsburgh, PA 15232
    Phone+1 412-692-4724

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2010 - 2013
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 2007 - 2010
  • Duke University School of Medicine
    Duke University School of MedicineClass of 2007

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2007 - 2024
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...
    Alison R. Sehgal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
    Alison R. Sehgal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Includi...
    Alison R. Sehgal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial ... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Leukemia Cure Raises Hope for More Patients
    Leukemia Cure Raises Hope for More PatientsFebruary 13th, 2022
  • New Graft Strategy May Improve Outcomes for Blood Stem Cell Recipients
    New Graft Strategy May Improve Outcomes for Blood Stem Cell RecipientsJanuary 10th, 2022
  • UPMC Partners with Be the Match, Stem Cell Registry
    UPMC Partners with Be the Match, Stem Cell RegistryJuly 28th, 2021
  • Join now to see all